Integra LifeSciences Reports Second Quarter 2026 Financial Results

About this update from Integra Lifesciences Holdings Corporation

PRINCETON - Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, reported financial results for the second quarter ending June 30, 2026 . Second Quarter 2026 Highlights Second quarter revenues of $418.8 million increased 0.8% on a reported basis and 0.7% on an organic basis compared to the prior year. Second quarter GAAP earnings per diluted share of $0.06 , compared to $(6.31) in the prior year. Adjusted earnings per diluted share of $0.56 , compared to $0.45 in the prior year. The Company is updating its reported revenue guidance range to $1.654 billion to $1.695 billion to reflect the impact of a stronger U.S . dollar on foreign exchange rates. The Company is reaffirming its 2026 full-year organic revenue growth guidance of 0.8% to 3.3% and adjusted earnings per share guidance of $2.40 to $2.50 . The Company initiated production at its Braintree manufacturing facility and remains on track for the planned fourth-quarter relaunch of SurgiMend. 'Our second-quarter performance reflects meaningful progress on our most important priorities. We are improving supply reliability, advancing quality, and returning products to market with discipline. The Braintree facility is now producing and ramping to support the planned SurgiMend relaunch later this year,' said Stuart Essig , Chairman and CEO of Integra LifeSciences . 'At the same time, we are seeing the benefits of a more aligned commercial organization while we continue to reduce our balance sheet leverage. Supported by our broad portfolio, attractive markets, and focused leadership team, we are strengthening our operating foundation and enhancing our ability to deliver sustainable long-term shareholder value.' Second Quarter 2026 Consolidated Performance Total reported revenues of $418.8 million increased 0.8% on a reported basis and 0.7% on an organic basis compared to the prior year. The Company reported GAAP gross margin of 52.5%, compared to 50.4% in the second quarter of 2025. Adjusted gross margin was 61.3%, compared to 60.7% in the prior year. Adjusted EBITDA for the second quarter of 2026 was $78.4 million , or 18.7% of revenue, compared to $71.2 million , or 17.1% of revenue, in the prior year. The Company reported GAAP net income of $4.5 million , or $0.06 per diluted share, in the second quarter of 2026, compared to GAAP net loss of $(484.1) million , or $(6.31) per diluted share, in the prior year. Adjusted net income for the second quarter of 2026 was $43.7 million , or $0.56 per diluted share, compared to $34.4 million , or $0.45 per diluted share, in the prior year. Second Quarter 2026 Segment Performance Specialty Surgery (70% of Revenues) Total revenues were $309.3 million , representing reported growth of 1.7% and an organic growth of 1.6% compared to the second quarter of 2025. Sales in Neuro increased 1.9% on an organic basis primarily driven by growth in Certas Plus, Bactiseal and CUSA. Sales in Instruments grew 3.2% on an organic basis. ENT sales declined (1.9%) as MicroFrance ENT instrument growth was offset by declines in other products. Tissue Reconstruction (30% of Revenues) Total revenues were $109.5 million , representing reported and organic declines of (1.9)% and (2.0)% respectively compared to the second quarter of 2025. Key drivers for the quarter include: Mid-single digit decline in wound reconstruction, driven by strong growth in DuraSorb and the relaunch of PriMatrix, offset by declines in MicroMatrix and Integra Skin. Integra Skin faced a prior year comparison that included the clearance of back orders in the second quarter of 2025. Sales in private label grew 4.7%. Balance Sheet, Cash Flow and Capital Allocation The Company generated cash flow from operations of $22.8 million in the quarter. Net debt at the end of the quarter was $1.6 billion , and the consolidated total leverage ratio was 4.1x. As of the end of the quarter, the Company had total liquidity of approximately $496 million , including $274.1 million in cash plus short-term investments and the remainder available under its revolving credit facility. 2026 Revenue and Adjusted Earnings Per Share Guidance For the third quarter of 2026, the Company expects reported revenues in the range of $410 million to $425 million , representing reported growth of 2.0% to 5.7% and organic growth of 1.9% to 5.7%. The Company expects adjusted EPS in the range of $0.53 to $0.61 per share. The Company is updating its reported revenue outlook from a range of $1.662 billion to $1.702 billion to a range of $1.654 billion to $1.695 billion to reflect the impact of a stronger U.S . dollar on foreign exchange rates. For the full year 2026, the Company is reaffirming its organic revenue growth guidance of 0.8% to 3.3% and adjusted earnings per share guidance of $2.40 to $2.50 . The adjusted EPS outlook reflects updated tariff assumptions, a higher interest rate environment, and potential debt refinancing actions. The Company's organic sales growth guidance for the third quarter and full year excludes the impact of acquisitions, divestitures, and foreign currency. About Integra Integra LifeSciences (Nasdaq: IART) is a global medical technology leader dedicated to restoring lives. We are advancing transformational care through impactful innovation in neurosurgery and tissue reconstruction, specialized fields that demand exceptional expertise and precision. Our portfolio of highly differentiated, gold-standard technologies are trusted by healthcare professionals to deliver life-saving care. Forward-Looking Statements This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties and reflect the Company's judgment as of the date of this release. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements. Some of these forward-looking statements may contain words like 'will,' 'believe,' 'may,' 'could,' 'would,' 'might,' 'possible,' 'should,' 'expect,' 'intend,' 'forecast,' 'guidance,' 'plan,' 'anticipate,' 'target,' or 'continue,' the negative of these words, other terms of similar meaning or they may use future dates. Forward-looking statements contained in this news release include, but are not limited to, statements concerning: future business, operational and financial performance and the Company's expectations and plans with respect to market opportunity, business and operational performance, strategic initiatives, capabilities, resources, manufacturing capabilities, product development, product availability and regulatory approvals, including expectations regarding the Company's Braintree facility and the the relaunch of SurgiMend in the fourth quarter of 2026. It is important to note that the Company's goals and expectations are not predictions of actual performance. Such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from predicted or expected results. Such risks and uncertainties include, but are not limited, to the following: increased geopolitical instability and other macroeconomic factors, including trade barriers and related restrictions (including tariffs and related countermeasures), armed conflict and acts of terrorism, geopolitical tension and instability, supply chain disruptions, and interest rate and foreign currency rate fluctuations, on the Company's suppliers, vendors and customers and on the Company's business and financial condition, results of operations and cash flows; the Company's ability to execute its financial, strategic and operating plans effectively; the Company's ability to remediate quality systems violations; difficulties in implementing the Company's compliance master plan; difficulties or delays in obtaining and maintaining required regulatory approvals, including the costs thereof; potential difficulties, delays and disruptions in manufacturing, distribution or sale of products; the failure of the company's suppliers, vendors, and other third parties to meet contractual, regulatory and other obligations; the anticipated development of markets the Company sells its products into and the success of the Company's products in these markets; the Company's ability to predict accurately the demand for its products and products under development; increasing industry competition; the coverage and reimbursement decisions of third-party payors; trends toward health care cost containment; difficulties in controlling expenses, including costs to procure and manufacture the Company's products; the ability of the Company to successfully manage leadership and organizational changes and the impact of changes in management or staff levels; the impact of goodwill and intangible asset impairment charges if future operating results of acquired businesses are significantly less than the results anticipated at the time of the acquisitions, the geographic distribution of where the Company generates its taxable income; changes to applicable laws, regulations and enforcement guidance, including tax laws and global health care reforms; fluctuations in foreign currency exchange rates; the amount of our bank borrowings outstanding and other factors influencing liquidity; breaches, failures or other disruptions of our or our vendors' or customers' information technology systems or products and the economic, competitive, governmental, technological, and other risk factors and uncertainties identified under the heading 'Risk Factors' included in Item 1A of Integra's Annual Report on Form 10-K for the year ended December 31, 2025 and information contained in subsequent filings with the Securities and Exchange Commission. These forward-looking statements are made only as of the date hereof, and the Company undertakes no obligation to update or revise the forward-looking statements, whether as a result of new information, future events, or otherwise, except as otherwise required by law. Contact: Chris Ward Tel: (609) 772-7736 Email: [email protected] Laurene Isip Tel: (609) 208-8121 Email: [email protected] (C) 2026 Electronic News Publishing, source ENP Newswire

View stock analysis, news, and events for Integra Lifesciences Holdings Corporation